News & Updates

INESSS in Quebec Approves Opdivo as Exceptional Drug Status

Immunotherapy Opdivo (nivolumab) has been approved with Exceptional Drug Status in Quebec for the treatment of NSCLC!

Lung Cancer Connection - Winter 2017

Winter may be officially over (finally!) but check out LCC's Lung Cancer Connection Winter 2017 Newsletter!

pERC Issues Positive FINAL Recommendation for Zykadia

Today, the pCODR Expert Review Committee (pERC) issued the Final Recommendation for ceritinib (Zykadia) resubmission for NSCLC.  pERC recommends reimbursement of ceritinib (Zykadia) monotherapy for patients with ALK positive locally NSCLC.

This is more great news for lung cancer patients!  Lung Cancer Canada encourages the pan-Canadian Pricing Alliance (pCPA) to begin negotiations as soon as possible so that patients are not left waiting for much needed therapy.

Ontario Latest Province to Cover Cost of Immuno-Oncology Treatment OPDIVO® (nivolumab)

Bristol-Myers Squibb Canada Co. (BMS Canada) today announced that Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care have agreed to cover the cost of the immuno-oncology treatment OPDIVO® for three different difficult-to-treat tumour types, effective March 20, 2017.

pCOCR-CADTH Releases Positive Initial Reccomendation for Tagrisso

More good news for NSCLC patients!  Both lung cancer drugs Tagrisso (osimertinib) and Zykadia (ceritinib) received positive initial recommendations from pCODR-CADTH.

Major Step Forward in Accessing New Life-Extending Medication

Major Step Forward in Accessing New Life-Extending Medication for Advanced Metastatic Lung, Melanoma and Kidney Cancer Patients.

Canadian lung, melanoma and kidney cancer patients are one step closer to gaining access to immunotherapy after pCPA negotiations have concluded. Provinces and Territories are encouraged to list quickly.
 

CCO is Introducing a Lung Cancer Screening Pilot

Cancer Care Ontario is introducing a lung cancer screening pilot program for people at high risk in April 2017.

Faces of Lung Cancer Report 2016

Ottawa, ON, November 1, 2016 – The third annual Faces of Lung Cancer Report is released and inspires a message of hope as Lung Cancer Canada charts a path forward to improve the dire situation for Canadian patients. In 2016, multiple sources clearly demonstrated the level of progress that still needs to be made in Canada, specifically when it comes to lung cancer research, rising rates of the disease in women and the consequences of lengthy approval and coverage timelines. [Read the News Release]

Stakeholder Briefing

New Research Shows Canadian Lung Cancer Patients Are Disadvantaged Compared to Their US Peers and Shocking Trends Among Women

Canadian Cancer Statistics 2016

The Canadian Cancer Society has released the Canadian Cancer Statistics 2016.  Lung cancer remains deadliest cancer for CDN men & women the lowest 5-year survival (17%) of any major cancer.

Displaying results 1-10 (of 37)
 |<  < 1 - 2 - 3 - 4  >  >|